<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416896</url>
  </required_header>
  <id_info>
    <org_study_id>BME-1</org_study_id>
    <secondary_id>R44DK059062</secondary_id>
    <nct_id>NCT01416896</nct_id>
  </id_info>
  <brief_title>New Needle for Two-Needle Hemodialysis</brief_title>
  <acronym>BME-1</acronym>
  <official_title>New Needle for Two-Needle Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedical Enterprises Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedical Enterprises Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our preliminary studies have demonstrated that an innovative new design of the hemodialysis
      venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the
      patient) with three jets is superior to the standard venous needle because it decreases the
      velocity and turbulence of the blood when compared with the standard venous needle, it is
      more efficient in the removal of toxins from the blood, and it is safe and effective. More
      importantly, our preliminary studies suggested that the new needle causes less damage to the
      dialysis vascular access and to circulating blood cells and less inflammation and oxidative
      stress. These will decrease medical complications, the high cost of care and death in
      dialysis patients. The current study will corroborate the finding of previous studies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net change in intracellular oxidative stress and intracellular proinflammatory cytokines levels</measure>
    <time_frame>4 hours of hemodialysis</time_frame>
    <description>The net change in the levels of intracellular IL-6, IL-6 soluble receptor, IL-6 gp130, superoxide, H2O2 and IL-1 during dialysis (difference between pre and post dialysis) using the new venous needle will be compared with the change using the current venous needle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net change in oxidative stress and proinflammatory cytokines in plasma</measure>
    <time_frame>4 hours hemodialysis</time_frame>
    <description>The net change in the plasma levels of IL-1, IL-6, MDA and AOPP during dialysis (difference between pre and post dialysis) using the new venous needle will be compared with the net change that occurs in patients using the current venous needle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>New venous needle, the &quot;BME needle&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis using the new venous needle, the &quot;BME needle&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard venous needle, the &quot;standard needle&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One hemodialysis using the standard venous needle, the &quot;standard needle&quot; (device).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodialysis using the standard venous needle</intervention_name>
    <description>Hemodialysis using the standard venous dialysis needle</description>
    <arm_group_label>Standard venous needle, the &quot;standard needle&quot;</arm_group_label>
    <other_name>hemodialysis using the standard venous dialysis needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodialysis using a new venous needle, the &quot;BME needle&quot;</intervention_name>
    <description>Hemodialysis using a new venous dialysis needle or the &quot;BME needle&quot;</description>
    <arm_group_label>New venous needle, the &quot;BME needle&quot;</arm_group_label>
    <other_name>The &quot;BME needle&quot; is a newly designed venous dialysis needle.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodialysis using a new venous needle, the &quot;BME needle&quot;</intervention_name>
    <description>One hemodialysis using a new venous needle, the &quot;BME needle&quot;</description>
    <arm_group_label>New venous needle, the &quot;BME needle&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodialysis using the standard venous needle</intervention_name>
    <description>One hemodialysis using the standard venous needle</description>
    <arm_group_label>Standard venous needle, the &quot;standard needle&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:(1) end stage renal disease receiving hemodialysis in an ambulatory
        outpatient dialysis facility (2) male or female, (3) ages 18-80, (4) arterio-venous graft
        or AV fistula as vascular access,

        Exclusion Criteria:patients with fever, infection, inflammation or malignancy will be
        excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo R Zarate, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Enterprises Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro A Jose, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children National Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro A Jose, MD, PhD</last_name>
    <phone>202-476-5715</phone>
    <email>pjose@cnmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>DaVita K Street Dialysis Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A Jose, MD, PhD</last_name>
      <phone>202-476-5715</phone>
      <email>pjose@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Pedro A Jose, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmedialysis.com</url>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>August 12, 2011</last_update_submitted>
  <last_update_submitted_qc>August 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alfredo Zarate, MD</name_title>
    <organization>Biomedical Enterprises Inc.</organization>
  </responsible_party>
  <keyword>End stage Renal Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

